| Stereochemistry | MIXED |
| Molecular Formula | C17H24O3 |
| Molecular Weight | 276.3707 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1CC(CC(C)(C)C1)OC(=O)C(O)C2=CC=CC=C2
InChI
InChIKey=WZHCOOQXZCIUNC-UHFFFAOYSA-N
InChI=1S/C17H24O3/c1-12-9-14(11-17(2,3)10-12)20-16(19)15(18)13-7-5-4-6-8-13/h4-8,12,14-15,18H,9-11H2,1-3H3
Cyclandelate is a vasodilator developed for the treatment of cardiovascular diseases. The drug was used in many countries for such diseases as intermittent claudication, arteriosclerosis obliterans, thrombophlebitis, nocturnal leg cramps, local frostbite, Raynaud's phenomenon. In the USA it was also approved for intermittent claudication and cognitive dysfunction in Alzheimer's disease under the name Cyclospasmol. Cyclandelate exerts its effect by blocking calcium channels and inhibiting smooth muscles contration. Cyclandelate was withdrawn from the market in the USA for lack of effectiveness.
CNS Activity
Originator
Approval Year
Doses
Sourcing
PubMed
Patents
Sample Use Guides
The usual dose of cyclandelaye is between 400 - 800 mg per day, given in two or four divided doses. If indicated, higher doses of 1200 mg to 1600 mg per day may be given in four divided doses before meals and at bedtime, for two to four weeks, and then reduced by 200 mg decrements to the usual dose.
Route of Administration:
Oral
Cyclandelate in concentrations between 10 and 50 uM induced a dose-dependent increase in the basal level of cytosolic Ca++ of unstimulated platelets. In platelets stimulated with thrombin (5 U/ml) or platelet activating factor (1 uM), cyclandelate strongly inhibited the increase of cystolic Ca++ in the presence of extracellular Ca++, but in the absence of extracellular Ca++ only a weak inhibition was observed. This inhibition was dose dependent and optimal at about 50 uM, the concentration at which Ca++ mobilisation was suppressed to about 10% of control values, and at which cyclandelate inhibits platelet aggregation.
ACTIVE MOIETY
